Figure 2.
Effects of SGLT-2 inhibitors on (a) HOSPITALIZATION FOR HEART FAILURE OR CARDIOVASCULAR DEATH and (b) MAJOR ADVERSE CARDIOVASCULAR EVENTS, by patient group and by trial
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.